Peripherally applied candesartan inhibits central responses to angiotensin II in conscious rats

Naunyn-Schmiedeberg's Archives of Pharmacology

Volumn 365, Issue 6, 2002, Pages 477-483

  Gohlke, P ^a,b,c   Kox, T ^a,b,c   Jurgensen T ^a,b,c   Von Kugelgen S ^a,b,c   Rascher, W ^a,b,c   Unger, T ^a,b,c   Culman, J ^a,b,c  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^b HUMBOLDT UNIVERSITY   (Germany)

^c UNIVERSITY HOSPITAL ERLANGEN   (Germany)

Author keywords

Angiotensin II; AT1 receptor antagonist; Candesartan; Drinking behaviour; Pressor response; Rat brain; Vasopressin

Indexed keywords

ANGIOTENSIN; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ARGIPRESSIN; CANDESARTAN; DRUG VEHICLE; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR; BENZIMIDAZOLE DERIVATIVE; TETRAZOLE DERIVATIVE;

ANIMAL EXPERIMENT; ARTICLE; BLOOD BRAIN BARRIER; BLOOD PRESSURE REGULATION; BRAIN REGION; CANNULA; CARDIOVASCULAR RESPONSE; CONSCIOUSNESS; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRINKING BEHAVIOR; DRUG EFFECT; FEMORAL VEIN; MALE; MICROINJECTION; NONHUMAN; PRESSOR RESPONSE; PROTEIN DETERMINATION; PROTEIN LOCALIZATION; RAT; THALAMUS MIDLINE NUCLEUS; VASOPRESSIN BLOOD LEVEL; VASOPRESSIN RELEASE; VEIN CATHETERIZATION; ANIMAL; BLOOD; BLOOD PRESSURE; DOSE RESPONSE; DRINKING; DRUG ANTAGONISM; PHYSIOLOGY; WAKEFULNESS; WISTAR RAT;

ANGIOTENSIN II; ANIMAL; ARGIPRESSIN; BENZIMIDAZOLES; BLOOD PRESSURE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRINKING; MALE; RATS; RATS, WISTAR; RECEPTORS, ANGIOTENSIN; TETRAZOLES; WAKEFULNESS; ANIMALS; ARGININE VASOPRESSIN; RECEPTOR, ANGIOTENSIN, TYPE 1;

EID: 0035987112     PISSN: 00281298     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00210-002-0545-y     Document Type: Article

References (35)

1. Cognitive enhancing actions of Dup 753 detected in a mouse habituation paradigm
2. Losartan potassium, a nonpeptide antagonist of angiotensin II, chronically administered p.o. does not readily cross the blood-brain barrier
3. A new formalin test allowing simultaneous evaluation of cardiovascular and nociceptive responses
4. Effects of systemic treatment with irbesartan and losartan on central responses to angiotensin II in conscious, normotensive rats
5. 1 receptors improves neurological outcome and reduces expression of AP-1 transcription factors after focal brain ischemia in rats
6. 1 receptor antagonists: The role of tight antagonist binding
7. Angiotensin, thirst, and sodium appetite
8. Cardiac and vascular effects of long-term losartan treatment in stroke-prone spontaneously hypertensive rats
9. Long-term inhibition of renin-angiotensin system sustains memory function in aged Dahl rats
10. Antihypertensive effects of a highly potent and long-acting angiotensin II subtype-1 receptor antagonist, (±)-1-(cyclohexyloxycarbonyl-oxy) ethyl 2-ethoxy-1-{[2′-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-1H- benzimidazole-7-carboxylate (TCV-116), in various hypertensive rats
11. Further localization of cardiovascular and behavioral actions of substance P in the brain
12. Endogenous brain angiotensin II disrupts passive avoidance behavior in rats
13. Functional evidence that the angiotensin antagonist losartan crosses the blood-brain barrier in the rat
14. Repeated measurements and multiple comparisons in cardiovascular research
15. Angiotensin injected into the neostriatum after learning disrupts retention performance
16. 1-receptor blockers in isolated vessels of different origin
17. Pharmacological profile of a novel nonpeptide angiotensin II subtype 1 receptor antagonist, TCV-116
18. 1 blockade normalizes cerebrovascular autoregulation and reduces cerebral ischemia in spontaneously hypertensive rats
19. Chronic peripheral administration of the angiotensin II AT (1) receptor antagonist candesartan blocks brain AT (1) receptors
20. 1-R mRNA antisense
21. 1 receptor antagonists to cross the blood-brain barrier in rats
22. 1 receptors in the supraoptic nucleus
23. Vasopressin in the plasma of stroke-prone spontaneously hypertensive rats
24. Brain and pituitary angiotensin
25. Pharmacological profile of a highly potent and long-acting angiotensin II receptor antagonist, 2-ethoxy-1-{[2′-(1H-tetrazol-5-yl)biphenyl-4-yl]-methyl}-1H- benzimidazole-7-carboxylic acid (CV-11974), and its prodrug, (±)-1-(cyclohexyloxycarbonyloxy)-ethyl 2-ethoxy-1-{[2′-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-1H- benzimidazole-7-carboxylate (TCV-116)
26. Access of peripherally administered DuP 753 to rat brain angiotensin receptors
27. Inhibition of the angiotensin II type 1 receptor by TCV-116: Quantification by in vitro autoradiography
28. Brain angiotensin: Pathways and pharmacology
29. 1 receptors
30. Involvement of adrenergic and angiotensinergic receptors in the paraventricular nucleus in the angiotensin II-induced vasopressin release
31. Angiotensin II receptor antagonist CV-11974 and cerebral blood flow autoregulation
32. 1) receptor antagonist candesartan cilexetil (TCV-116) and the angiotensin converting enzyme inhibitor enalapril in rats
33. Nonpeptide angiotensin II receptor antagonists. VIII. Characterization of functional antagonism displayed by DuP 753, an orally active antihypertensive agent
34. 1 angiotensin II receptors in rat brain, kidney and adrenals demonstrated by in vitro autoradiography